Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomised, Double-Blind, Placebo-Controlled, First in Human Study of the Safety, Tolerability and Pharmacokinetics of a Single Dose of PRV-002 in Healthy Volunteers.

Next Previous
X
Search
Trial Profile

A Phase 1, Randomised, Double-Blind, Placebo-Controlled, First in Human Study of the Safety, Tolerability and Pharmacokinetics of a Single Dose of PRV-002 in Healthy Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PRV-002 (Primary)
  • Indications Traumatic brain injuries
  • Focus Adverse reactions; First in man
  • Sponsors Odyssey Health

    • Most Recent Events

    • 17 May 2024 According to an oragenics media release, the company will host a webinar panel on Neurotrauma Medicine Monday, May 20, 2024 and will present its lead drug candidate, ONP-002, to treat mild TBI and discuss its outcomes from preclinical and Phase I trials, as well as details of an upcoming Phase II clinical trial to be conducted in acute and emergency departments.
    • 02 Jan 2024 According to an Odyssey Pharmaceuticals Inc media release, the company is preparing for a Phase 2 clinical study in the first half of 2024
    • 28 Sep 2022 Results published in the Odyssey Group International Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top